Thoraflex Hybrid
Vascutek, Ltd. · Decision date Apr 19, 2022
What did the FDA approve?
FDA records P210006 as an original PMA application. The recorded decision is approval, dated Apr 19, 2022.
FDA approval order statement
Approval for the Thoraflex Hybrid. The device is intended for the open surgical repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta in cases of aneurysm and/or dissection.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 19, 2022
Regulatory record facts
- Identifier
- P210006
- Regulatory pathway
- Premarket approval application
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- Decision code
- APPR
- Decision date
- Apr 19, 2022
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P210006 received
Application receipt date recorded by FDA.
P210006 · FDA decision
APPR
P210006/S018 · Related supplement
Thoraflex Hybrid
Timeline entries are records held by MedtechLedger for P210006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Thoraflex HybridP210006/S018 | Vascutek, Ltd. | PMA supplement | Sep 8, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vascutek, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Newmains Ave., Inchinnan, PA49RR
Sources and methodology
- Original FDA record: P210006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records